The CLEAR winner in Covid-19 Antigen testing

The CovClear Rapid Antigen test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal swab specimens directly collected

  • Simple to use - Rapid Results in 3-10 Minutes

  • Highly Sensitive and Specific – Outperforming other antigen tests

  • Safety Advantage – Sealed Vial Protecting Collector Against Live Virus

  • No Reader Required - Reduced Cost

  • No Cassette Needed - Reduced Material Wastage

  • Early Detection - Reduced Exposure

  • Researched, developed & manufactured in the USA

PERFORMANCE
97% Sensitivity
97%

Sensitive

96.8% Positive
100%

Specific

Validated by San Diego, CA

Intended Use


CovClear Rapid Antigen Test results are for the identification of the SARS-CoV-2 nucleocapsid protein antigen. The antigen is generally detectable in nasal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status.

Sample Collection

1

Remove a swab from the pouch.

2

Place the dry swab into one of the patient’s nostrils until it reaches resistance.

3

Slowly rotate the swab 7 times over the surface inside the nostril.

4

Slowly remove the swab from the nostril while still rotating it. Repeat steps 2-4 on other nostril.

Test Instructions

1

Pour entire buffer solution ampule into empty vial.

2

Insert dry swab into one nostril until you meet resistance. Swirl 7 times. Repeat with the same swab in other nostril.

3

Place swab into prepared vial with buffer solution. Slightly swirl the vial and swab for 30 seconds.

NOTE: DO NOT place the cap on the vial. DO NOT remove the swab.

4

Press tip against side of vial to squeeze liquid from swab for 10 seconds. Then place swab back into the buffer solution.

NOTE: DO NOT remove the swab.

5

Place new test strip, arrow pointing down, into vial with the swab.

NOTE: Touch test strip on the colored end only.

6

Place cap securely onto the vial with the test strip and swab inside.

NOTE: Cap will permanently lock in place. DO NOT tip vial over as this will invalidate the test.

READ RESULTS AFTER 3 MINUTES
DO NOT READ RESULTS PAST 20 MINUTES

Interpretation of Results

Clinical Performance

A total of 76 blinded dry nasal swab samples were tested in one investigational site to evaluate the clinical performance of the CovClearTM SARS-Cov-2 Rapid Antigen Test strip. Nasal swab specimens were collected from patients with COVID-19 like symptoms during the 2020 COVID-19 season. All the Nasal swabs were added to the CovClearTM vial (either dry or in buffer). All the Nasal swab specimens were confirmed as positive or negative and validated with Ct value by the FDA EUA RT-PCR as a comparator method. The samples were randomized, blinded and tested using the instructions provided by the Instruction for Use.

All the study samples were random and assigned a study ID prior to testing. The expected results of the sample were completely blinded to the operators. 11% of the positive samples had Ct values over 30.

Analytical Sensitivity: Limit of Detection (LoD)

The LoD for direct swab was established using heat-inactivated SARS-CoV-2 isolate Hong Kong/VM20001061/2020). The strain was spiked into 0.5 saline solution prepared in accordance with BAM R66. The estimated LoD found from the initial two- fold serial dilution test was confirmed by testing 20 replicates. The confirmed LoD for direct swab was 7.12 x 103 TCID50/ml.

Specimen Stability:

The specimen stability was established using heat-inactivated SARS-CoV-2 isolate Hong Kong/VM20001061/2020. The strain was spiked into 0.5% saline solution at 3x the LoD (2.16 x 104 TCID50/ml). Samples were then Incubated at room temperature for 0, 2 6, and 24 hours respectively prior to testing. All samples tested produced no qualitative impact on test line signal intensity as compared to the 0-hour condition, demonstrating that the CovClear™ COVID-19 Antigen Test performance was not affected by sample Instability for up to 24 hours at room temperature.

Analytical Specificity: Cross Reactivity and Microbial Interference

The potential cross-reactivity (exclusivity) of a panel of common organisms was evaluated with SARS-CoV-2 negative samples using the CovClear™ COVID-19 Antigen Test. Potential microbial interference was evaluated with samples containing heat-inactivated SARS-CoV-2 isolate isolate Hong Kong/VM20001061/2020 at approximately 3x LoD. A total of 7 bacteria were tested at a target at approximately 1 x 106 cfu/ml. The 13 viruses were tested at concentrations between 9.87 x 104 and 1 x 105 pfu. All negative samples gave negative results at the concentrations of the potentially cross-reactive common organisms tested showing no cross-reactivity with CovClear™ COVID-19 Antigen assay. All samples with SARS-CoV-2 strain tested positive showing no microbial interference at the concentrations of the potentially interfering common organisms tested.

SARS-coronavirus was not tested as part of this study. Additional testing may be required to determine if this pathogen will generate cross-reactivity at the CovClear test line.

To estimate the likelihood of cross-reactivity with SARS-CoV-2 of organisms that were not available for wet testing, in silico analysis using the Basic Local Alignment Search Tool (BLAST) managed by the National Center for Biotechnology Information (NCBI) was used to assess the degree of protein sequence homology.

  • https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins&PROGRAM=blastp&BLAST_PROGRAMS=blastp&PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&DATABASE=n/a&QUERY=&SUBJECTS=
  • The homology between SARS-CoV-2 nucleocapsid protein and human coronavirus HKU1 nucleocapsid protein is relatively low, at 36.7% across 86.4% of sequences, but cross- reactivity cannot be ruled out.
  • The homology between SARS-CoV-2 nucleocapsid protein and Mycobacterium tuberculosis total protein (3,991 proteins) is relatively low, homology-based cross-reactivity can be ruled out.
  • The homology between SARS-CoV-2 nucleocapsid protein and Pneumocystis jirovecii total protein (3,745 proteins) is relatively low, homology-based cross-reactivity can be ruled out.
  • The homology between SARS-CoV-2 nucleocapsid protein and human coronavirus 229E nucleocapsid protein is relatively low, but cross- reactivity cannot be ruled out. However, a result of the cross-reactivity wet study showed that CovClear™ COVID-19 Antigen had no cross-reactivity against human coronavirus 229E.
  • No homologous protein was detected as a result of in silico assay with the proteins of Mycoplasma pneumoniae and the nucleocapsid protein (NP) of SARS-CoV-2. So, cross-reactivity of CovClear™ COVID-19 Antigen against Mycoplasma pneumoniae can be ruled out.

Endogenous Interfering Substances Effect

To assess substances with the potential to interfere with the performance of the CovClear™ COVID-19 Antigen, positive and negative samples were tested with the addition of potentially interfering substances. The SARS-CoV-2 target concentration in the positive samples was approximately 2x LoD. All samples tested produced no qualitative impact to test line signal intensity, demonstrating that the CovClear™ COVID-19 Antigen Test performance was not affected by any of the 14 potentially interfering substances listed in the table below at the concentrations tested.

The interfering effects of biotin concentrations ranging between 625 ng/mL and 10 µg/mL were tested in a separate study. Biotin concentrations up to 1.25 µg/ml did not lead to false results. Biotin concentrations ≥2.5 µg/ml can cause false-negative COVID-19 results with the CovClear™ COVID-19 Antigen.

High-dose Hook Effect

The CovClear™ COVID-19 Antigen was tested up to 1.15 x 105 TCID50/ml of heat-inactivated SARS- CoV-2 strain and no high-dose hook effect was observed.

Technical Support

For questions, or to report a problem, please call Empowered Diagnostics at 954-354-2768.

Test system problems may also be reported to the FDA using the MedWatch reporting system (phone: 1-800-FDA-1088; fax: 1-800-FDA-1078: or http://www.fda.gov/medwatch).

Keys X
keys
keys
attrs
edit